

## **Recent articles on Pharmacovigilance from “Medical Writing” Journal**

EMA releases the revised Good Pharmacovigilance Practices Module V - updated guidance on risk management plans. Tiziana von Bruchhausen and Sven Schirp; Volume 26, Issue 2 (September, 2017) pp. 48 - 51

The changing face of (benefit-)risk management. Lesley Wise; Volume 24, Issue 2 (June, 2015) pp. 62–65

Pharmacovigilance medical writing: An evolving profession. Tiziana von Bruchhausen; Kerstin Prechtel; Volume 24, Issue 2 (June, 2015) pp. 66–71

A shot at demystifying the risk management plan for medical writers. Sandra Götsch; Volume 24, Issue 2 (June, 2015) pp. 72–76

Using social media as the patient's voice in the benefit-risk assessment of drugs: Are we ready? Massoud Toussi, Lisa Chamberlain James, Sir Alasdair Breckenridge; Volume 24, Issue 2 (June, 2015) pp. 77–81

The MHRA perspective on the new pharmacovigilance legislation. Mick Foy; Volume 21, Issue 2 (June, 2012) pp. 128 – 130

Medical writing for two audiences – The RMP public summary. Kerstin Prechtel, Stefanie Rechtsteiner; Volume 24, Issue 4 (Dec, 2015) pp. 200-2004

## **EMWA Symposium on Risk Management and Risk Benefit Evaluation**

EMWA members can view presentations from EMWA's One-Day Symposium on Risk Management and Risk Benefit Evaluation held in May 2015 by going to [http://www.emwa.org/EMWA/Conferences/EMWA\\_Symposia/EMWA/Conferences/EMWA\\_Symposia.aspx?hkey=0ddcc866-8344-4f96-8505-162cdae16b5d](http://www.emwa.org/EMWA/Conferences/EMWA_Symposia/EMWA/Conferences/EMWA_Symposia.aspx?hkey=0ddcc866-8344-4f96-8505-162cdae16b5d)

- Overview of risk-benefit evaluation – Art Gertel
- The European Medicines Agency perspective – Juan Garcia
- Medical writer's perspective – Sven Schirp
- Industry perspective – Peter Verdru
- Patient perspective – Erik Briers
- Patient perspective – David Gilbert